Breast cancer patients receiving medium and high risk chemotherapy
Conditions
Interventions
Breast cancer patients receiving medium and high risk chemotherapy (Mecapegfilgrastim Injection):None
Sponsors
QingHai University Affiliated Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old; 2.The patient signed an informed consent form and voluntarily joined this study; 3.Pathological or histocytological diagnosis of any type of breast cancer and treatment of breast cancer with medium high risk chemotherapy; 4.Researchers determine that patients can accept the use of thiopheniramine;
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Individuals allergic to sulfamethoxazole, polyethylene glycol recombinant human granulocyte colony-stimulating factor, recombinant human granulocyte colony-stimulating factor, and other preparations expressed in Escherichia coli; 3.Unable to understand the nature of the research or without obtaining informed consent; 4.The patient is undergoing other clinical intervention studies; 5.Researchers determine other situations that are not suitable for inclusion in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Countries
China
Contacts
Public ContactZhao Jiuda
QingHai University Affiliated Hospital
Outcome results
None listed